NAD+ Injections vs NMN Supplements: Where the Evidence Stands
Oral NMN, subcutaneous NAD+, IV NAD+ — they all aim to raise the same cellular cofactor, but the routes and evidence differ substantially.
NAD+ (nicotinamide adenine dinucleotide) is a cellular cofactor essential to mitochondrial energy production, sirtuin signaling, and DNA repair. NAD+ levels decline measurably with age, and replenishing them has become one of the most active areas of longevity research.
The three main approaches
Oral NMN (nicotinamide mononucleotide) is the most accessible — a precursor that the body converts to NAD+. Oral NR (nicotinamide riboside) is the closely related alternative, with the most published human data. Subcutaneous NAD+ injection delivers the molecule directly. IV NAD+ infusion is the most aggressive route, used in clinics and longevity practices.
What the human evidence shows
For oral NR, multiple human trials (Conze 2019, Martens 2018) confirm reliable elevation of blood NAD+ levels — typically 40–90% over baseline at doses of 300–1,000 mg daily. Clinical outcome data is more limited; cardiovascular and metabolic markers improve modestly in some studies.
For oral NMN, the FDA's 2022 ruling reclassified it as a drug rather than a supplement, complicating availability. Pre-ruling studies showed similar pharmacokinetics to NR.
For subcutaneous and IV NAD+, pharmacokinetic data shows the molecule does reach circulation, but large randomized outcome trials are lacking.
The mechanism case is strong; the outcomes case is partial
Animal and cell models consistently show NAD+ restoration produces metabolic and longevity benefits. Human outcomes — actual improvements in healthspan, function, or disease — are less well-established. This is an honest summary of where the field stands in 2026.
Practical guidance
Oral NR at 300–600 mg daily is the best-evidenced consumer route. Subcutaneous NAD+ at 100–250 mg weekly is a reasonable clinical option for patients seeking higher delivery without IV infusions. IV NAD+ is the most invasive and expensive route; its incremental benefit over subcutaneous in most patients is not well-established.
Sources & references
Peer-reviewed studies, clinical guidelines, and regulatory documents used to write this article.
- 1.Martens CR et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286.— Nature Communications, 2018.
- 2.Conze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of NIAGEN. Sci Rep. 2019;9:9772.— Scientific Reports, 2019.
- 3.Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372:1224-1229.— Science, 2021.
How this article was written: Researched and drafted by the Valora Rx editorial team using current peer-reviewed literature and clinical practice guidelines from bodies including the Endocrine Society, AUA, NAMS, ACOG, and FDA. This article is informational and is not a substitute for individualized medical advice from your physician. Read our editorial standards →
